GeneDx price to book ratio WGS
Market value divided by the book value of the company's net assets, since 2020.
- Today, Nov 2, 2026
- 7.8×
- 6-year median
- 5.9×
- Against its 6-year history
- 58th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 0.1× to 191×
- Peer median
- 3.0×
GeneDx's price to book ratio is 7.8× as of Nov 2, 2026.
That is above its 6-year median of 5.9×, close to the middle of its last 6 years.
Over that time it ranged from 0.1× in Nov 2023 to 191× in Mar 2021.
The median for 10 hospital and care facility stocks of a similar size is 3.0×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.8× | 4.8× | 13.4× |
| 2025 | 13.2× | 6.6× | 16.5× |
| 2024 | 10.5× | 0.3× | 10.6× |
| 2023 | 0.3× | 0.1× | 1.1× |
| 2022 | 0.2× | 0.2× | 2.8× |
| 2021 | 2.8× | 2.8× | 191× |
| 2020 | 122× | 111× | 128× |
Against its peers
Companies in Medical - Care Facilities nearest GeneDx's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| WGSGeneDx | 7.8× |
| HCSGHealthcare Services | 3.3× |
| ARDTArdent Health | 1.2× |
| PGNYProgyny | 5.0× |
| ADUSAddus HomeCare | 2.0× |
| MDPediatrix Medical | 2.8× |
| PNTGPennant | 3.9× |
| PRVAPrivia Health | 3.5× |
| AVAHAveanna Healthcare | 10.0× |
| USPHU S Physical Therapy | 2.8× |
| NHCNational Healthcare | 2.8× |
| Peer median | 3.0× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on GeneDx
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.